Clinical Trial Update: Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1 [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 safety trial evaluating an NY-ESO-1 protein vaccine for cancers expressing NY-ESO-1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• NY-ESO-1 protein vaccine (NY-ESO-1 protein vaccine)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Neoplasms | Phase 1 | Status: COMPLETED